How to Buy L3Harris: A Cheap Drone Stock With an AI Kicker

L3Harris' VAMPIRE launcher, using BAE Systems' $22,000 APKWS rockets, can intercept roughly $50,000 Shahed drones at a fraction of the cost of a $2 million Patriot interceptor. L3Harris shares have fallen 16% in the past month and 35% from their earlier-year high following the CEO's dismissal, leaving the company at about 16.9x trailing free cash flow on $2.7B of FCF and 24x earnings. The company also licensed Shield AI's Tracker C-UAS technology to improve drone detection and targeting, a potential catalyst for VAMPIRE sales; the article estimates the stock trades about 10% below fair value.

Analysis

The relevant earnings lever is not the advertised interceptor-to-target cost ratio, but whether LHX can convert deployed-system visibility into funded, repeatable orders for launchers, sensors, integration, training and sustainment. C-UAS procurement is likely to favor layered architectures rather than a single vendor, so RTX, NOC, KTOS and AVAV can capture adjacent radar, command-and-control, interceptor and attritable-drone spend even if LHX wins launcher placements. BAE’s APKWS exposure is economically attractive, but BAESY’s U.S. ADR liquidity makes it a less efficient vehicle than LHX or a broader defense basket.

LHX’s discount should not be treated as purely a temporary governance multiple: the key question is whether disruption delays program execution, capital allocation or customer confidence. Over the next 1-3 months, a credible permanent CEO appointment, reaffirmed cash-conversion guidance and disclosed C-UAS order backlog would support multiple normalization; absent those, the stock can remain cheap despite favorable end-market narratives. Over 6-18 months, the structural upside is a shift in defense budgets toward high-volume, lower-cost interceptors and sensors, but this also creates pricing pressure as programs move from urgent buys to competitive programs of record.

The contrarian view is that the market may already understand the strategic relevance while underestimating the time required for appropriations, testing and export approvals to become revenue. A highly publicized deployment or AI licensing announcement is not proof of material sales, exclusivity, or margin expansion; Shield AI can license the same capability to competing primes. The thesis is falsified if LHX reduces free-cash-flow guidance, shows weak order growth in ISR/C-UAS-related businesses, or if management turnover broadens beyond the CEO role.

Key Decisions for Investors

• Initiate a modest 3-6 month long LHX / short RTX pair only after LHX reaffirms annual free-cash-flow guidance or identifies a permanent CEO; target 10-15% relative outperformance from governance-discount compression. Exit if LHX cuts FCF guidance or the relative spread widens another 10%.
• Use LHX as the preferred single-name C-UAS recovery exposure rather than BA (Boeing has no direct read-through here) or illiquid BAESY ADRs; scale entries around the next earnings report rather than chase defense-headline strength.
• Maintain a watch alert for disclosed VAMPIRE, APKWS or related C-UAS backlog/order values and production-rate commitments. Upgrade the position only if orders demonstrate recurring program funding rather than isolated operational deployments.
• For broader conflict-risk exposure, favor a diversified long ITA or XAR basket over an outsized LHX position until management execution risk clears; this preserves exposure to C-UAS budget expansion while reducing single-company governance risk.